Discover 4,573 paid clinical trials in New York State. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
New York State presents a wide array of paid research opportunities for both healthy volunteers and those with specific health concerns. Actively recruiting research institutions in New York City, Buffalo, and Rochester offer access to innovative treatments and exceptional medical care near you.
Filter
1
Filter results
Results: 4,573
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
Location: Boston MA, Buffalo NY, Columbus OH, Detroit MI,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06292780
Phase 1, Phase 2, Recruiting
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Location: North Haven CT, Lake Success NY, Chapel Hill NC,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06413680
Phase 1, Phase 2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer
for
Non-Small Cell Lung Cancer
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center
Sex: All
Age: 18+
Code: NCT05424029
Recruiting
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
for
Brain and Central Nervous System Tumors
Location: Garden City NY
Sponsor: Center for Molecular Medicine
Sex: All
Age: 18+
Code: NCT00004129
Phase 1, Recruiting
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
for
Prostate Cancer
Location: Boston MA, Worcester MA, New Haven CT, Quebec,
Sponsor: Prostate Cancer Clinical Trials Consortium
Sex: Male
Age: 21+
Code: NCT03151629
Recruiting
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
for
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early,
Location: New York NY, Richmond VA, Durham NC, Miami FL,
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Sex: All
Age: 18 - 70+
Code: NCT05832229
Phase 2, Recruiting
Rifaximin to Modify the Disease Course in Sickle Cell Disease
for
Sickle Cell Disease, Antibiotics
Location: Valhalla NY
Sponsor: New York Medical College
Sex: All
Age: 18 - 70
Code: NCT03719729
Phase 2, Recruiting
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
for
Brain Cancer, Glioma
Location: New York NY
Sponsor: Memorial Sloan Kettering Cancer Center
Sex: All
Age: 18+
Code: NCT00870129
Recruiting
Acceptance and Commitment Therapy for HIV+ Hazardous Drinkers
for
HIV-1-infection, Alcohol Drinking
Location: Syracuse NY
Sponsor: Syracuse University
Sex: All
Age: 18+
Code: NCT06648629
Recruiting
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
for
Metastatic HER2-positive Breast Cancer
Location: Boston MA, Providence RI, Quebec, Long Island City NY,
Sponsor: Jazz Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06435429
Phase 3, Recruiting
Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System
for
Chronic Heart Failure, CKD Stage 3
Location: New York NY, Rochester NY, Greensboro NC, Asheville NC,
Sponsor: AquaPass Medical Ltd.
Sex: All
Age: 21 - 70+
Code: NCT06360380
Recruiting
Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia
Sponsor: Weill Medical College of Cornell University
Sex: All
Age: 18+
Code: NCT05447689
Recruiting
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)